HK Stock Market Move | IMPACT THERAP-B (07630) rose more than 10% in late trading; the EU marketing application for senaparib is expected to be approved this month.

IMPACT THERAP-B (07630) rose more than 10% in late trading. As of press time, it was up 6.02% at HK$8.895, with turnover of HK$68.7001 million. On the news front, Impact Therapeutics announced that the board has resolved to use no more than HK$100 million to repurchase H shares on the open market, with all required funds coming from the company's own capital. In addition, the company may, depending on market conditions, further repurchase H shares within the repurchase mandate granted by the shareholders' meeting. It is worth noting that senaparib received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in September. Goldman Sachs said that Impact Therapeutics management stated at the GS Asia Healthcare Corporate Day that the EU marketing application for senaparib is expected to be approved this month, based on the positive CHMP opinion already obtained in September.